查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1867050

霍乱疫苗市场按疫苗类型、给药途径、剂型、给药方法、分销管道、最终用户、年龄层和应用进行划分－2025-2032年全球预测

Cholera Vaccines Market by Vaccine Type, Route Of Administration, Dosage Form, Presentation Type, Distribution Channel, End User, Age Group, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，霍乱疫苗市场规模将达到 5.4959 亿美元，复合年增长率为 7.54%。

主要市场统计数据
基准年 2024 3.0702亿美元
预计年份：2025年 3.2981亿美元
预测年份：2032年 5.4959亿美元
复合年增长率 (%) 7.54%

一份权威的介绍，概述了霍乱疫苗的最新进展、供应挑战以及公共卫生领导者和行业相关人员的策略重点。

霍乱仍然是全球公共卫生关注的焦点，疫苗领域的进步对预防和疫情应对策略至关重要。本执行摘要总结了产品创新、监管动态、分销管道和相关人员采纳方面的关键趋势，旨在为公共卫生领导者、生产商和投资者提供参考。它简洁而又全面地概述了霍乱疫苗技术的现状、影响疫苗取得和供应的因素，以及指导采购和部署的实际考虑。

疫苗配方创新、适应性监管管道和不断变化的计画预期，正推动疫苗接种和普及进程发生显着转变，加速疫苗的推广和普及。

霍乱疫苗领域正经历变革性的转变，这主要得益于科学创新、政策重点的调整以及供应链结构的改善。製剂技术的进步使得口服製剂更加稳定，部分产品的耐热性也得到提升，从而减轻了低温运输压力，并拓宽了可行的分销模式。同时，多个司法管辖区的监管管道也变得更加灵活，能够加快在疫情环境中展现出显着疗效的疫苗的审批流程。

分析2025年新关税对供应链、采购选择和采购实务的营运和策略影响

2025年美国关税政策为全球霍乱疫苗生态系统中的製造商、经销商和采购负责人带来了额外的营运考量。进口关税及相关合规要求的变化影响了某些零件和成品的成本结构，导致供应链相关人员重新评估筹资策略和与国际合作伙伴的合约条款。为此，一些製造商加大了零件本地化生产的力度，或对替代供应商进行资格认证，以维持供应的连续性并降低关税波动带来的风险。

深入分析揭示了疫苗类型、给药途径、製剂形式、包装、分销管道、最终用户、年龄层和应用方法如何决定产品和项目的选择。

细分市场洞察揭示了产品属性和供应环境如何影响临床效用、商业策略和专案契合度。根据疫苗类型，该领域将疫苗分为注射剂和口服剂型，每种管道都存在独特的临床、物流和接受度的考量。注射剂疫苗非常适合寻求持久免疫反应的临床环境，而口服疫苗通常在大规模宣传活动或快速应对疫情时优先考虑易于给药。肌肉注射和口服给药途径的差异会影响医护人员训练、病患接受度和医疗服务地点的选择。肌肉注射通常需要经过训练的人员和严格的锐器管理，而口服给药则减轻了这些操作负担，并有助于扩大社区宣传活动的覆盖范围。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合即时流行病学监测数据，优化高风险地区的霍乱疫苗分发
  • 开发一种耐热口服霍乱疫苗，以应对偏远地区低温运输物流挑战
  • 评估单剂口服霍乱疫苗在紧急情况和疫情应变的有效性
  • 透过公共卫生机构和疫苗生产商之间的合作，促进民众获得价格合理的霍乱疫苗。
  • 增强黏膜免疫的减毒活霍乱疫苗製剂研发进展
  • 在人口密集的贫民窟地区实施以社区为基础的方法，以提高霍乱疫苗接种覆盖率
  • 低收入流行地区下一代霍乱结合疫苗的监管核准流程
  • 气候变迁和人口迁移模式如何影响霍乱发病率并塑造疫苗部署策略

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 霍乱疫苗市场（依疫苗类型划分）

  • 注射疫苗
  • 口服疫苗

9. 霍乱疫苗市场依给药途径划分

  • 肌肉内注射
  • 口服

第十章 霍乱疫苗市场（以剂型划分）

  • 液体
  • 冷冻干燥

11. 霍乱疫苗市场按剂型划分

  • 多剂量
  • 单一剂量

12. 霍乱疫苗市场按分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 霍乱疫苗市场（依最终用户划分）

  • 门诊治疗中心
  • 诊所
  • 医院
  • 研究设施

14. 按年龄组别分類的霍乱疫苗市场

  • 成人
  • 老年人
  • 儿童

第十五章 霍乱疫苗市场（依应用领域划分）

  • 预防
  • 治疗

16. 各地区霍乱疫苗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章 霍乱疫苗市场（依群体划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

18. 各国霍乱疫苗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章 竞争情势

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • EuBiologics Co., Ltd.
    • Shantha BIoTechnics Private Limited
    • Incepta Vaccine Ltd.
    • Sanofi Pasteur SA
    • Valneva SE
    • Emergent BioSolutions Inc.
    • Bharat BIoTech International Limited
Product Code: MRR-5D693B46BD1B

The Cholera Vaccines Market is projected to grow by USD 549.59 million at a CAGR of 7.54% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 307.02 million
Estimated Year [2025] USD 329.81 million
Forecast Year [2032] USD 549.59 million
CAGR (%) 7.54%

An authoritative introduction that frames current cholera vaccine advancements, delivery challenges, and strategic priorities for public health leaders and industry stakeholders

Cholera remains a global public health concern, and the evolving landscape of vaccines is central to prevention and outbreak control strategies. This executive summary synthesizes critical developments across product innovation, regulatory progress, distribution channels, and stakeholder adoption to inform public health leaders, manufacturers, and investors. It provides a concise but comprehensive orientation to the current state of cholera vaccine technologies, the forces reshaping access and delivery, and the practical considerations that guide procurement and deployment.

In the following pages, readers will find context on vaccine types, administration routes, formulation choices, presentation formats, and end-user settings, as well as the implications of geopolitical and trade dynamics. The summary is designed to be actionable: it highlights where scientific advances intersect with programmatic realities and where commercial opportunities align with public health priorities. By framing these themes up front, decision-makers can rapidly identify candidate areas for deeper investigation and immediate action.

Compelling landscape shifts driven by formulation innovation, adaptive regulatory pathways, and evolving programmatic expectations that accelerate vaccine deployment and access

The cholera vaccine landscape is undergoing transformative shifts driven by scientific innovation, renewed policy attention, and improvements in supply chain architecture. Advances in formulation science have enabled more stable oral preparations and improved thermostability for some products, which in turn ease cold-chain burdens and broaden the range of feasible distribution models. Parallel to these technological changes, regulatory pathways have become more adaptive in several jurisdictions, facilitating accelerated reviews for vaccines that demonstrate demonstrable benefits in outbreak contexts.

At the same time, stakeholder expectations are evolving. Public health authorities increasingly demand evidence of real-world effectiveness and programmatic suitability, not just immunogenicity. Funders and procurement agencies are prioritizing vaccines that can be deployed quickly in emergency settings and that integrate into routine immunization programs. Consequently, manufacturers are balancing investment between novel platforms and incremental improvements to existing oral and injectable offerings. Taken together, these shifts are reshaping competitive dynamics, opening new channels for collaboration, and elevating the importance of integrated planning across clinical, regulatory, and supply functions.

Analysis of the operational and strategic effects of newly implemented United States tariffs in 2025 on supply chains, sourcing choices, and procurement practices

Tariff policies enacted by the United States in 2025 have introduced additional operational considerations for manufacturers, distributors, and procurers engaged in the global cholera vaccine ecosystem. Changes in import duties and related compliance requirements have affected the cost profile of certain components and finished products, prompting supply chain stakeholders to reassess sourcing strategies and contractual terms with international partners. In response, some manufacturers have intensified efforts to localize component production or to qualify alternative suppliers to maintain continuity of supply and to mitigate exposure to tariff volatility.

Furthermore, procurement teams and international agencies have adapted tender structures and pricing negotiations to reflect the new trade environment. These adaptations include longer-term supply agreements with clearer allocation terms and contingency clauses that address tariff-related cost fluctuations. Importantly, the tariff adjustments have also underscored the value of supply chain transparency and traceability, encouraging greater investment in analytics and scenario planning to preserve programmatic resilience. While tariffs represent a macro-level shift, their most tangible impacts emerge through operational changes at manufacturing sites, distribution hubs, and procurement desks.

Deep segmentation-driven insights revealing how vaccine type, administration route, formulation, presentation, distribution, end-user, age group, and application determine product and program choices

Segmentation insights illuminate how product attributes and delivery contexts shape clinical utility, commercial strategy, and programmatic fit. Based on vaccine type, the field differentiates between injectable vaccine options and oral vaccine formulations, with each pathway carrying distinct clinical, logistical, and acceptance considerations; injectable vaccines may align with clinical settings seeking durable immune responses, whereas oral vaccines often prioritize ease of administration during mass campaigns and rapid outbreak response. Based on route of administration, distinctions between intramuscular and oral delivery influence provider training, patient acceptance, and site-of-care selection; intramuscular routes typically require trained personnel and sharps management, while oral administration reduces those operational burdens and can expand reach in community campaigns.

Based on dosage form, liquid and lyophilized presentations present trade-offs related to stability, reconstitution requirements, and cold-chain dependencies; liquid forms facilitate rapid deployment, while lyophilized formulations can extend shelf life under certain storage profiles. Based on presentation type, multi dose and single dose packaging choices affect wastage rates, storage space, and per-administration cost dynamics; multi dose vials may improve supply efficiency in high-throughput settings but necessitate stringent protocols to prevent contamination. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways each offer unique access points that influence uptake patterns, patient counseling opportunities, and reimbursement interactions; hospital pharmacies commonly support institutional immunization programs, online pharmacies enable direct-to-consumer access in regulated contexts, and retail pharmacies provide convenient touchpoints for routine immunization. Based on end user, diverse delivery environments such as ambulatory centers, clinics, hospitals, and research facilities impose differing logistical and clinical requirements that manufacturers must account for in product design and support services. Based on age group, adult, geriatric, and pediatric segments drive formulation, dosing, and safety monitoring priorities because immune response and risk profiles vary across the lifespan. Based on application, prophylactic and therapeutic use cases determine evidence needs, with prophylactic vaccination focusing on prevention and population-level protection, while therapeutic applications demand data regarding use in outbreak containment or as adjuncts to clinical care. Collectively, these segmentation dimensions guide targeted product development, tailored messaging for providers and payers, and differentiated commercialization strategies that align with the operational realities of delivery environments.

Regional dynamics that shape regulatory approaches, procurement modalities, manufacturing linkages, and deployment strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics materially influence policy priorities, regulatory approaches, and supply chain architectures for cholera vaccination programs. In the Americas, public health systems tend to emphasize integration of vaccines into established immunization schedules and contingency planning for localized outbreaks, supported by public procurement frameworks that favor transparent contracting and centralized distribution. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory environments and health system capacities, where regional coordination mechanisms and donor-funded initiatives play a large role in harmonizing access and standardizing emergency response protocols.

Meanwhile, the Asia-Pacific region demonstrates a combination of manufacturing capacity growth and large, diverse population needs that create both opportunity and complexity. Across these geographies, regional manufacturers and global suppliers must adapt to varying cold-chain infrastructures, differing regulatory timelines, and distinct stakeholder expectations. As a result, successful strategies increasingly couple technical product attributes with tailored market access plans that reflect local procurement models, reimbursement mechanisms, and public health priorities. Transitional investments in regional distribution hubs and capacity-building programs further influence how quickly and effectively vaccination efforts scale in response to epidemiological signals.

Corporate strategic directions and partnership models that determine competitive advantage through manufacturing scale, platform innovation, and programmatic support commitments

Competitive positioning among leading companies reflects divergent strategies around innovation, supply agreements, and partnerships with public health institutions. Some organizations emphasize platform investments that enable rapid iteration of oral and injectable candidates, while others concentrate on optimizing manufacturing processes and expanding fill-finish capacity to meet the needs of large-scale campaigns. Strategic alliances between commercial manufacturers and global health agencies have become common, focused on jointly addressing affordability, supply predictability, and distribution to hard-to-reach populations.

Additionally, companies that invest in programmatic support services-such as training, cold-chain solutions, and post-market surveillance systems-tend to strengthen their value propositions with national immunization programs and large procurers. Intellectual property strategies and manufacturing licensing arrangements also influence market access; technology transfers to regional producers can accelerate local availability but require careful management of quality assurance and regulatory compliance. Overall, competitive differentiation increasingly rests on the ability to align product attributes with implementation realities, maintain resilient supply networks, and demonstrate commitment to public health outcomes through measurable program support.

Practical and prioritized strategic actions for manufacturers and public health partners to align product design, supply resilience, pricing, and programmatic support for maximal impact

Actionable recommendations for industry leaders emphasize aligning scientific development with practical delivery and stakeholder engagement. First, prioritize product design decisions that account for end-user contexts and distribution realities, ensuring that formulation and packaging choices reduce logistical friction and support rapid outbreak response. Second, invest in diversified supplier networks and regional manufacturing partnerships to mitigate trade and tariff exposure while enhancing responsiveness to local demand. Third, augment commercial offerings with programmatic support such as training, cold-chain innovation, and post-deployment surveillance to strengthen relationships with health authorities and procurers.

Moreover, develop flexible contracting and pricing frameworks that recognize the constraints of public-sector purchasers and international donors, and incorporate contingency clauses that address regulatory or trade disruptions. Finally, commit to transparent data-sharing arrangements and collaborative research partnerships that accelerate evidence generation around real-world effectiveness and safety, thereby building confidence among clinicians, policymakers, and communities. Taken together, these recommendations encourage a balanced approach that integrates scientific rigor, operational resilience, and stakeholder-centered engagement.

A robust mixed-methods research framework combining expert interviews, literature synthesis, and triangulated analysis to ensure evidence-based and actionable insights

The research methodology underpinning this report employed a mixed-methods approach that combined comprehensive literature synthesis, expert interviews, and qualitative analysis of policy and procurement documents. Primary research included structured consultations with vaccine developers, supply chain specialists, and immunization program managers to gather firsthand perspectives on operational challenges and opportunities. Secondary research integrated peer-reviewed studies, regulatory filings, and programmatic guidance to corroborate themes and ensure an evidence-based narrative.

Analytical frameworks emphasized triangulation: insights derived from stakeholder interviews were cross-checked against documented regulatory developments and published clinical outcomes to strengthen validity. Where appropriate, scenario analysis was used to explore operational implications of trade and policy shifts, and sensitivity testing helped highlight potential points of vulnerability in supply networks. Throughout, quality assurance processes ensured that data sources were critiqued for relevance and recency, and that conclusions reflected convergent evidence rather than isolated observations.

A forward-looking conclusion emphasizing the convergence of innovation, supply resilience, and stakeholder collaboration necessary to translate vaccine advances into public health gains

In conclusion, the cholera vaccine domain is at an inflection point where scientific advances, supply chain modernization, and evolving policy demands are converging to reshape how vaccines are developed, procured, and delivered. Innovations in formulation and presentation expand the toolkit available to public health practitioners, while changes in trade and procurement practices remind stakeholders of the need for operational agility. As a result, success will favor organizations that integrate technical excellence with pragmatic programmatic support and resilient commercial strategies.

Looking ahead, sustained collaboration between manufacturers, health authorities, funders, and regional production partners will be essential to translate scientific progress into meaningful reductions in disease burden. By adopting the strategic priorities outlined here-centered on product suitability, supply chain diversification, and stakeholder engagement-actors across the ecosystem can improve preparedness for outbreaks and enhance routine protection. These coordinated efforts will ultimately determine the degree to which vaccine innovations realize their full public health potential.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of real-time epidemiological surveillance data to optimize cholera vaccine distribution in high-risk regions
  • 5.2. Development of thermostable oral cholera vaccines to address cold chain logistics challenges in remote areas
  • 5.3. Evaluation of single-dose oral cholera vaccine efficacy in emergency and outbreak response settings
  • 5.4. Partnerships between public health agencies and vaccine manufacturers to accelerate affordable cholera vaccine access
  • 5.5. Advancements in live attenuated cholera vaccine formulations aimed at enhancing mucosal immunity
  • 5.6. Implementation of community engagement initiatives to boost cholera vaccination uptake rates in densely populated slums
  • 5.7. Regulatory approval processes for next-generation cholera conjugate vaccines in endemic low-income countries
  • 5.8. Impact of climate change and migration patterns on cholera outbreak frequency shaping vaccine deployment strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cholera Vaccines Market, by Vaccine Type

  • 8.1. Injectable Vaccine
  • 8.2. Oral Vaccine

9. Cholera Vaccines Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Oral

10. Cholera Vaccines Market, by Dosage Form

  • 10.1. Liquid
  • 10.2. Lyophilized

11. Cholera Vaccines Market, by Presentation Type

  • 11.1. Multi Dose
  • 11.2. Single Dose

12. Cholera Vaccines Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Cholera Vaccines Market, by End User

  • 13.1. Ambulatory Centers
  • 13.2. Clinics
  • 13.3. Hospitals
  • 13.4. Research Facilities

14. Cholera Vaccines Market, by Age Group

  • 14.1. Adult
  • 14.2. Geriatric
  • 14.3. Pediatric

15. Cholera Vaccines Market, by Application

  • 15.1. Prophylactic
  • 15.2. Therapeutic

16. Cholera Vaccines Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Cholera Vaccines Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Cholera Vaccines Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. EuBiologics Co., Ltd.
    • 19.3.2. Shantha Biotechnics Private Limited
    • 19.3.3. Incepta Vaccine Ltd.
    • 19.3.4. Sanofi Pasteur S.A.
    • 19.3.5. Valneva SE
    • 19.3.6. Emergent BioSolutions Inc.
    • 19.3.7. Bharat Biotech International Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHOLERA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHOLERA VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CHOLERA VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CHOLERA VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS CHOLERA VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. CHOLERA VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. CHOLERA VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CHOLERA VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CHOLERA VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CHOLERA VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INJECTABLE VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INJECTABLE VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INJECTABLE VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INJECTABLE VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INJECTABLE VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INJECTABLE VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LYOPHILIZED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHOLERA VACCINES MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CHOLERA VACCINES MARKET SIZE, BY MULTI DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHOLERA VACCINES MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CHOLERA VACCINES MARKET SIZE, BY MULTI DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHOLERA VACCINES MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CHOLERA VACCINES MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHOLERA VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CHOLERA VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHOLERA VACCINES MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CHOLERA VACCINES MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHOLERA VACCINES MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CHOLERA VACCINES MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CHOLERA VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AMBULATORY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AMBULATORY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AMBULATORY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AMBULATORY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHOLERA VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CHOLERA VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHOLERA VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CHOLERA VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CHOLERA VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CHOLERA VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RESEARCH FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RESEARCH FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RESEARCH FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RESEARCH FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RESEARCH FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RESEARCH FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CHOLERA VACCINES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CHOLERA VACCINES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CHOLERA VACCINES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CHOLERA VACCINES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CHOLERA VACCINES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CHOLERA VACCINES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CHOLERA VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CHOLERA VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS CHOLERA VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS CHOLERA VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS CHOLERA VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE CHOLERA VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN CHOLERA VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 307. GCC CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GCC CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GCC CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. GCC CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. GCC CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 312. GCC CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 313. GCC CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 314. GCC CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 315. GCC CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. GCC CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. GCC CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. GCC CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. GCC CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. GCC CHOLERA VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. GCC CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 322. GCC CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 323. GCC CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 324. GCC CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 340. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 342. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 343. BRICS CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLI